Progress in ARDS research: a protection racket?

J Dakin, T W Evans

The acute respiratory distress syndrome in adults (ARDS) may complicate a wide variety of serious medical and surgical conditions, not all of which involve the lung directly. The pathogenesis remains unclear, but involves neutrophil recruitment to the alveoli and inflammatory pathway activation leading to increased permeability of the alveolar-capillary membrane and disordered vascular control, manifest clinically as pulmonary oedema formation and refractory hypoxaemia. Compliance is reduced and work of breathing is increased to the extent that most patients require endotracheal intubation and mechanical ventilatory support. Despite the recent publication of within-centre studies showing a fall in mortality, some 40–60% of patients with ARDS fail to survive with most of the deaths being attributable to multiple organ system failure.

It has been appreciated for some years that mechanical ventilation can itself exacerbate pre-existing alveolar injury. This may develop directly as a result of barotrauma and so called “volutrauma”, or indirectly through the adverse effects of increasing the inspired oxygen concentration to obviate hypoxaemia. Thus, studies in experimental animals have suggested that injury rises markedly above an end inspiratory (or plateau) pressure of 35 cm H₂O. Secondly, computed tomographic scanning in patients with ARDS subjected to varying levels of positive end expiratory pressure (PEEP) has shown that dependent consolidated areas of lung tend to remain poorly compliant and underventilated, and the application of conventional tidal volumes of the order of 10 ml/kg can overdistend the spared functioning regions. Consequently, the last decade has seen the emergence of ventilation strategies characterised by lower tidal and minute volumes. The cost of such an approach is reduced alveolar ventilation, which may further compromise oxygenation and CO₂ elimination. To accommodate this, target arterial haemoglobin saturation has been reduced to 90%, or slightly less, without compromising oxygen delivery. Higher respiratory rates of up to 35 breaths/min may be needed. Reduced CO₂ elimination necessitates tolerating respiratory acidosis or correction with bicarbonate. Finally, the application of levels of PEEP above the lower inflection point of the pulmonary pressure-volume curve increases functional residual capacity with a view to keeping more alveoli open throughout the respiratory cycle, thereby reducing shear (the so called “open lung strategy”).

The precise mode of ventilation applied to achieve these physiological end points has varied and studies have provided conflicting evidence concerning efficacy. Thus, an early randomised trial of tidal volumes of <6 ml/kg, a driving pressure above PEEP (titrated to the lower inflection point) of 20 cm H₂O, and permissive hypercapnia compared with conventional support in patients with early ARDS showed a significant survival advantage (38% mortality) although mortality in the control group (70%) was also high. By contrast, subsequent studies limiting end inspiratory pressures to 25 cm H₂O and tidal volumes to <10 ml/kg showed no mortality benefit, and patients at high risk of ARDS subjected to pressure (30 cm H₂O) and volume limited ventilation (8 ml/kg) showed no increase in survival compared with conventionally supported controls. However, the results of a recently published, large scale trial performed in 861 patients by the US acute respiratory distress syndrome network (ARDSNET) have been more encouraging. Within 36 hours of the onset of refractory hypoxaemia sufficiently severe to meet the American-European consensus guidelines criteria for acute lung injury (ALI, Pao₂/Fio₂ <300 mm Hg) in the presence of bilateral pulmonary infiltrates on chest radiography, subjects were randomised to conventional (10 ml/kg) or low volume ventilatory support (5 ml/kg); 75% of those in each group had developed ALI/ARDS in association with sepsis, pneumonia, or aspiration. The trial was stopped after interim analysis revealed mortality of 39.8% in the conventionally supported group and 31% in the lower tidal volume group, a reduction of 22%. There were subtle, but probably significant, differences between the experimental protocol employed by the ARDSNET trialists and those of previous negative studies. Firstly, with respect to both tidal volume per actual body weight and plateau pressure, the two arms of this trial were further separated than any other. Although a volume cycled approach was employed, ventilation was frequently adjusted to maintain pressure levels, permitting wider tidal volume constraints. The mean plateau pressures recorded for the high and low volume arms, respectively, were therefore 33 and 25 cm H₂O compared with pressure differences of the order of 4.5–6.0 cm H₂O in the trials with negative results. Secondly, to attain the low plateau pressure in the protective ventilatory group tidal volumes of 5 ml/kg were used, which is lower than those used in previous trials. (Although the protocol stipulated 6 ml/kg, this was per kg of weight predicted from measured height. The actual weight of their population exceeded this by an average of 20%, reducing the actual tidal volume applied to nearer 5 ml/kg.)

Thirdly, in the ARDSNET study bicarbonate was used to correct the acidosis resulting from CO₂ retention, a contentious innovation given recent evidence suggesting that buffering hypercapnic acidosis may worsen ALI.

Not surprisingly, these results have been hailed as a significant advance in that they are the first to demonstrate mortality benefit of any intervention applied to patients with severe lung injury in a randomised controlled fashion. Is such optimism justified, especially as most of the patients with ARDS who fail to survive succumb to multiorgan system failure? In fact, the current results complement a growing body of experimental evidence which suggest that high volume, high pressure ventilation may propagate alveolar inflammation. Furthermore, in the past year a landmark study in patients with ARDS revealed that high tidal volume ventilatory support can not only increase alveolar inflammation, but also disseminate inflammatory cytokines into the systemic circulation. What, then, are the implications of this study for those clinicians involved in the care of patients with severe ALI? Two conclusions seem irrefutable. Firstly, ventilator strategy does seem to influence outcome and protective strategies aimed principally at reducing tidal volume in order to restrict plateau pressures should be introduced. Secondly, the results highlight the importance of the injured lung as the potential source of a systemic inflammatory response with potentially fatal consequences. In this sense inappropriate ventilation can clearly impact adversely on mortality.

By contrast, a number of important questions remain unanswered. Firstly, is a single approach to ventilation appropriate for all patients with acute severe lung injury? Recent studies suggest that patients with direct alveolar
injury leading to ARDS may have differing physiological characteristics and ventilatory responses from those suffering indirect pulmonary insults. The ARDSNET study made no attempt to stratify patients in this fashion and enrolled patients with ALI as well as ARDS. Moreover, patients were enrolled within 36 hours of the onset of lung injury, although ARDS is a condition passing through exudative, inflammatory, and fibroproliferative histopathological phases over some 2–3 weeks; optimal ventilatory support may therefore change as the condition evolves. Secondly, aiming consistently for a tidal volume of 5 ml/kg may be inappropriate, especially if it necessitates bicarbonate infusion. Thirdly, these results suggest that a re-evaluation of extreme approaches to lung protection incorporated in high frequency oscillation and extracorporeal supportive techniques may be appropriate. Non-invasive (face mask) positive pressure ventilation might have similarly beneficial effects and has already been used successfully in these circumstances.

In summary, the ARDSNET investigation in a sense confirms what we have suspected for some years—that lung protection is the name of the game. How far and how best this approach should be applied to improve mortality further in patients with ARDS still remains to be seen.

This work was supported in part by the British Lung Foundation.

Correspondence to: Professor T W Evans
t.evans@rbh.nthames.nhs.uk

Unit of Critical Care,
Imperial College School of Medicine,
Royal Brompton Hospital,
London SW3 6NP, UK

J DA  KIN
T W EVANS
